Tivozanib approved in US for treatment of adult patients with relapsed or refractory advanced renal cell carcinoma who have received ≥2 prior systemic therapies

Approval for this oral, next-generation vascular VEGF tyrosine kinase inhibitor is and is based on data from phase 3 TIVO-3 study (n=350) comparing it to sorafenib, which reported superior progression free survival (median 5.6 vs. 3.9 months, HR 0.73; 95% CI: 0.56, 0.95; p=0.016)

Biospace Inc.